Literature DB >> 62263

Immunological abnormalities in patients who had the oculomucocutaneous syndrome associated with practolol therapy.

P O Behan, W M Behan, F J Zacharias, J T Nicholls.   

Abstract

Patients with and without adverse reactions on practolol therapy showed altered immune responses. There was cutaneous anergy to Candida albicans and streptokinase/streptodornase antigens and depression of lymphocyte function in vitro. Anticomplementary activity and a wide range of autoantibodies were found in patients who had received practolol.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 62263     DOI： 10.1016/s0140-6736(76)90831-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  7 in total

1.  Irreversible protein binding of [14C]-practolol metabolite(s) to hamster liver microsomes (proceedings).

Authors:  T C Orton; C Lowery; W E Lindup
Journal:  Br J Pharmacol       Date:  1977-06       Impact factor: 8.739

2.  Metabolism of immunoglobulin A, lymphocyte function, and histocompatibility antigens in patients on anticonvulsants.

Authors:  R A Shakir; P O Behan; H Dick; D G Lambie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-04       Impact factor: 10.154

3.  Postmarketing surveillance of the safety of cimetidine.

Authors:  I K Crombie
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-25

4.  Toxicology of the immune system.

Authors:  G E Davies
Journal:  Histochem J       Date:  1981-09

5.  Childhood accidents--an endemic of epidemic proportion.

Authors:  J R Sibert; G B Maddocks; B M Brown
Journal:  Arch Dis Child       Date:  1981-03       Impact factor: 3.791

6.  Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for adverse reaction.

Authors:  I A Mackie; D V Seal; J M Pescod
Journal:  Br J Ophthalmol       Date:  1977-05       Impact factor: 4.638

7.  Comparison of methods to detect side-effect on clinical application of chloranolol, a beta-adrenergic receptor inhibitor.

Authors:  E Török; E Kósa; M Szontagh; P Juvancz; J Eggenhofer; J Borvendég
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.